The operator of South Korea's stock markets has decided to allow traders to resume buying and selling shares of Samsung Biologics.<br />The company is accused of intentionally breaking accounting rules to inflate its profits.<br />But the Exchange said Monday, after a meeting of its Corporate Review Committee,... that in the interest of maintaining the company's continuity and transparency -- and to protect investors -- trading will resume today.<br />The company was suspended a month ago after the findings by the Financial Services Commission. <br />
